Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
Opinion|Articles|April 18, 2025
50 years of visionary innovation: Leading ophthalmologists reflect on the field’s greatest breakthroughs
Author(s)Martin David Harp
Celebrating a half-century of progress with Ophthalmology Times.
Advertisement
Advertisement
In honor of Ophthalmology Times’ 50th anniversary, we asked a panel of leading ophthalmologists and optometrists across subspecialties to reflect on the most transformative innovations in the field over the past 5 decades. From diagnostics to therapeutics, surgery to gene therapy, the insights reveal just how far ophthalmology has come—and hint at an even more promising future.
Related to this article
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
Advertisement
Advertisement